TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07197645: Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain

Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 33 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,036,728

Rescue Site Savings

+$691,152

Unlock Full NCT07197645 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07197645 Rescue Dossier →